IAFFALDANO, PIETRO
 Distribuzione geografica
Continente #
NA - Nord America 292
EU - Europa 189
AS - Asia 40
OC - Oceania 7
AF - Africa 4
SA - Sud America 2
Totale 534
Nazione #
US - Stati Uniti d'America 284
IT - Italia 84
DK - Danimarca 42
VN - Vietnam 16
GB - Regno Unito 14
DE - Germania 12
SE - Svezia 11
JP - Giappone 10
NL - Olanda 10
CA - Canada 8
AU - Australia 7
IN - India 5
AT - Austria 3
CH - Svizzera 3
EG - Egitto 3
IR - Iran 3
CN - Cina 2
ES - Italia 2
IE - Irlanda 2
TR - Turchia 2
CL - Cile 1
FR - Francia 1
GR - Grecia 1
LB - Libano 1
MK - Macedonia 1
NO - Norvegia 1
OM - Oman 1
PT - Portogallo 1
UA - Ucraina 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 534
Città #
Lyngby 34
Fairfield 28
Taranto 23
Ashburn 17
Dong Ket 16
Seattle 15
Bari 14
Columbus 13
Houston 11
Stockholm 10
Walsall 9
Cambridge 8
Buffalo 7
Milan 7
Woodbridge 7
Altamura 6
Fleming Island 6
Francavilla Fontana 6
Rome 6
Ann Arbor 5
Chicago 5
Aarhus 4
Cottbus 4
Las Vegas 4
London 4
San Diego 4
Bengaluru 3
Los Angeles 3
Nuremberg 3
Utrecht 3
Vienna 3
Wilmington 3
Amersfoort 2
Amsterdam 2
Basel 2
Berlin 2
Boardman 2
Cairo 2
Calgary 2
Cerdanyola del Vallès 2
Clifton 2
Columbia 2
Dallas 2
Denver 2
Footscray 2
Grottaglie 2
Kyoto 2
Melbourne 2
Mottola 2
Nakabaruhigashi 2
New York 2
Noicattaro 2
Providence 2
Shibuya 2
Southend-on-sea 2
Sumida 2
Al Mansurah 1
Balikesir 1
Barnet 1
Beirut 1
Bellevue 1
Bern 1
Boston 1
Boulder 1
Brisbane 1
Burnaby 1
Büdelsdorf 1
Cesena 1
Chiyoda-ku 1
Coimbatore 1
Cordon 1
Dordrecht 1
Dublin 1
Dulles 1
Edison 1
Empoli 1
Frankfurt am Main 1
Frederiksberg 1
Groningen 1
Guangzhou 1
Henderson 1
Herndon 1
Hillsboro 1
Isfahan 1
Kicevo 1
Kildare 1
Kingston 1
Lelystad 1
Malden 1
Marseille 1
Milpitas 1
Muizenberg 1
Muscat 1
Niagara Falls 1
Nichelino 1
Ordu 1
Oslo 1
Pasadena 1
Pieve di Cento 1
Pittsburgh 1
Totale 383
Nome #
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2, file dd9e0c64-a5a1-1e9c-e053-3a05fe0a45ef 131
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis, file dd9e0c67-c20d-1e9c-e053-3a05fe0a45ef 65
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis, file dd9e0c6a-8bd2-1e9c-e053-3a05fe0a45ef 60
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis, file dd9e0c67-f68d-1e9c-e053-3a05fe0a45ef 57
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort, file dd9e0c67-79a1-1e9c-e053-3a05fe0a45ef 47
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort, file dd9e0c64-9c73-1e9c-e053-3a05fe0a45ef 42
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial, file dd9e0c6a-188b-1e9c-e053-3a05fe0a45ef 36
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis, file dd9e0c68-f53e-1e9c-e053-3a05fe0a45ef 25
Predictors of long-term disability accrual in relapse-onset multiple sclerosis, file dd9e0c67-eb67-1e9c-e053-3a05fe0a45ef 18
Prognostic indicators in pediatric clinically isolated syndrome, file dd9e0c69-f007-1e9c-e053-3a05fe0a45ef 18
Durvalumab and multiple sclerosis: a causal link or simple unmasking?, file dd9e0c68-b33b-1e9c-e053-3a05fe0a45ef 6
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS, file dd9e0c66-f79c-1e9c-e053-3a05fe0a45ef 4
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France, file dd9e0c6b-9e2d-1e9c-e053-3a05fe0a45ef 4
Treatment decisions in multiple sclerosis-insights from real-world observational studies, file dd9e0c67-f5c1-1e9c-e053-3a05fe0a45ef 3
Sclerosi Multipla e Lavoro: dati preliminari, file dd9e0c66-e6e8-1e9c-e053-3a05fe0a45ef 2
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI, file dd9e0c67-3a30-1e9c-e053-3a05fe0a45ef 2
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome, file dd9e0c67-4a30-1e9c-e053-3a05fe0a45ef 2
null, file dd9e0c67-9274-1e9c-e053-3a05fe0a45ef 2
Multiple sclerosis registries in Europe – An updated mapping survey, file dd9e0c68-0fa6-1e9c-e053-3a05fe0a45ef 2
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis, file dd9e0c68-aa2b-1e9c-e053-3a05fe0a45ef 2
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide, file dd9e0c68-b32b-1e9c-e053-3a05fe0a45ef 2
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study, file dd9e0c6a-f1f3-1e9c-e053-3a05fe0a45ef 2
Disability assessment using Google Maps, file dd9e0c6b-8ba9-1e9c-e053-3a05fe0a45ef 2
Risk of Getting COVID-19 in People With Multiple Sclerosis, file dd9e0c6b-c022-1e9c-e053-3a05fe0a45ef 2
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica, file dd9e0c63-13c9-1e9c-e053-3a05fe0a45ef 1
null, file dd9e0c63-bb0d-1e9c-e053-3a05fe0a45ef 1
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients, file dd9e0c65-43d8-1e9c-e053-3a05fe0a45ef 1
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients, file dd9e0c67-bf11-1e9c-e053-3a05fe0a45ef 1
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients, file dd9e0c67-bf16-1e9c-e053-3a05fe0a45ef 1
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study, file dd9e0c67-bf18-1e9c-e053-3a05fe0a45ef 1
Natalizumab reduces serum pro-angiogenic activity in MS patients, file dd9e0c67-c060-1e9c-e053-3a05fe0a45ef 1
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study, file dd9e0c67-e1d5-1e9c-e053-3a05fe0a45ef 1
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register, file dd9e0c68-0820-1e9c-e053-3a05fe0a45ef 1
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study, file dd9e0c68-dc22-1e9c-e053-3a05fe0a45ef 1
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context, file dd9e0c6b-6762-1e9c-e053-3a05fe0a45ef 1
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method, file dd9e0c6b-8bbb-1e9c-e053-3a05fe0a45ef 1
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience, file dd9e0c6c-3534-1e9c-e053-3a05fe0a45ef 1
Totale 549
Categoria #
all - tutte 1289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1289


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0000 00 10 0040
2020/2021119 0001 328 1210 919829
2021/2022209 951115 1917 1613 23153729
2022/2023215 16194342 1916 2420 16000
Totale 549